DE60225433D1 - Verfahren zur herstellung von 1,3-substituierte indene und aryl-annellierte azapolycyclische verbindungen - Google Patents

Verfahren zur herstellung von 1,3-substituierte indene und aryl-annellierte azapolycyclische verbindungen

Info

Publication number
DE60225433D1
DE60225433D1 DE60225433T DE60225433T DE60225433D1 DE 60225433 D1 DE60225433 D1 DE 60225433D1 DE 60225433 T DE60225433 T DE 60225433T DE 60225433 T DE60225433 T DE 60225433T DE 60225433 D1 DE60225433 D1 DE 60225433D1
Authority
DE
Germany
Prior art keywords
annulated
aryl
preparation
substituted indenes
azapolycyclic compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60225433T
Other languages
English (en)
Other versions
DE60225433T2 (de
Inventor
Robert Alan Singer
Jason Daniel Mckinley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Publication of DE60225433D1 publication Critical patent/DE60225433D1/de
Application granted granted Critical
Publication of DE60225433T2 publication Critical patent/DE60225433T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C253/00—Preparation of carboxylic acid nitriles
    • C07C253/30—Preparation of carboxylic acid nitriles by reactions not involving the formation of cyano groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/45—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C255/47—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of rings being part of condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
DE60225433T 2001-04-20 2002-03-04 Verfahren zur herstellung von 1,3-substituierte indene und aryl-annellierte azapolycyclische verbindungen Expired - Fee Related DE60225433T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28513101P 2001-04-20 2001-04-20
US285131P 2001-04-20
PCT/IB2002/000660 WO2002085843A2 (en) 2001-04-20 2002-03-04 Process for the preparation of 1,3-substituted indenes and aryl-fused azapolycyclic compounds

Publications (2)

Publication Number Publication Date
DE60225433D1 true DE60225433D1 (de) 2008-04-17
DE60225433T2 DE60225433T2 (de) 2008-06-12

Family

ID=23092860

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60225433T Expired - Fee Related DE60225433T2 (de) 2001-04-20 2002-03-04 Verfahren zur herstellung von 1,3-substituierte indene und aryl-annellierte azapolycyclische verbindungen

Country Status (25)

Country Link
US (2) US7091372B2 (de)
EP (1) EP1383733B1 (de)
JP (1) JP2004527545A (de)
KR (1) KR100551183B1 (de)
CN (1) CN1321107C (de)
AR (2) AR035957A1 (de)
AT (1) ATE388135T1 (de)
AU (1) AU2002234836B2 (de)
BR (1) BR0208992A (de)
CA (1) CA2443946A1 (de)
CZ (1) CZ20032814A3 (de)
DE (1) DE60225433T2 (de)
DK (1) DK1383733T3 (de)
ES (1) ES2300430T3 (de)
HK (1) HK1062170A1 (de)
HU (1) HUP0303811A3 (de)
IL (1) IL157881A0 (de)
MX (1) MXPA03009527A (de)
PL (1) PL366657A1 (de)
PT (1) PT1383733E (de)
RU (1) RU2282619C9 (de)
TW (1) TWI244472B (de)
WO (1) WO2002085843A2 (de)
YU (1) YU78303A (de)
ZA (1) ZA200307205B (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60234268D1 (de) * 2001-11-16 2009-12-17 Cdt Oxford Ltd Leuchtdiode und verwendete verbindungen
MXPA05005517A (es) * 2002-11-25 2005-07-25 Pfizer Prod Inc Procedimiento mejorado para la preparacion de indenos 1,3-disustituidos.
RU2291862C2 (ru) * 2003-01-15 2007-01-20 Пфайзер Продактс Инк. Способ получения арилконденсированных полициклических лактамов
MXPA05013084A (es) * 2003-06-04 2006-03-02 Pfizer Prod Inc Preparacion de quinoxalinas sustituidas a partir de la dianilina con 2,3-dihidroxi-1,4-dioxano.
CA2533100A1 (en) * 2003-07-21 2005-01-27 Pfizer Products Inc. Aryl fused azapolycyclic compounds
DE602006013688D1 (de) * 2005-11-16 2010-05-27 Hoffmann La Roche Neues verfahren zur herstellung von thoc
DE102006024903A1 (de) * 2006-05-24 2007-11-29 Basf Ag Verfahren zur Vermeidung von Fumarsäureablagerungen bei der Herstellung von Maleinsäureanhydrid
RS52074B (en) * 2007-05-16 2012-06-30 Nycomed Gmbh PIRAZOLONE DERIVATED AS PDE4 INHIBITORS
EP2019107A1 (de) 2007-07-26 2009-01-28 Dynamit Nobel GmbH Explosivstoff- und Systemtechnik Verwendung von Phosphonium-Salzen in Kupplungsreaktionen und Verfahren zu ihrer Herstellung
WO2009065872A2 (en) * 2007-11-20 2009-05-28 Medichem, S.A. Improved processes for the synthesis of varenicline l-tartrate
WO2009101185A2 (en) * 2008-02-15 2009-08-20 Medichem, S.A. A NEW POLYMORPHIC FORM OF A PYRAZINO[2,3-h][3] BENZAZEPINE DERIVATIVE
WO2009143347A2 (en) * 2008-05-22 2009-11-26 Teva Pharmaceutical Industries Ltd. Varenicline tosylate, an intermediate in the preparation process of varenicline l-tartrate
US20090318695A1 (en) * 2008-06-19 2009-12-24 Vinod Kumar Kansal Processes for the preparation of varenicline and intermediates thereof
WO2010005643A1 (en) * 2008-07-10 2010-01-14 Teva Pharmaceutical Industries Ltd. Processes for purifying varenicline l-tartrate salt and preparing crystalline forms of varenicline l-tartrate salt
WO2010151524A1 (en) 2009-06-22 2010-12-29 Teva Pharmaceutical Industries Ltd Solid states forms of varenicline salts and processes for preparation thereof
US20120004239A1 (en) 2010-06-11 2012-01-05 Medichem, S.A. Process for Preparing Quinoxaline Derivatives
KR101603427B1 (ko) * 2014-08-14 2016-03-15 영남대학교 산학협력단 케스케이드 반응을 통한 인덴 유도체의 효율적 합성방법
CN104478803A (zh) * 2014-12-19 2015-04-01 连云港恒运医药科技有限公司 伐尼克兰中间体及其硝基还原杂质的制备方法
JP6956707B2 (ja) * 2015-08-14 2021-11-02 ボウロス アンド クーパー ファーマスーティカルズ プロプライエタリー リミテッドＢｏｕｌｏｓ ＆ Ｃｏｏｐｅｒ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｐｔｙ Ｌｔｄ アリール化合物の合成
US11084853B2 (en) 2016-07-07 2021-08-10 Howard Hughes Medical Institute Modified ligand-gated ion channels and methods of use
WO2019094778A1 (en) 2017-11-10 2019-05-16 Scott Sternson Modified ligand-gated ion channels and methods of use
CN111995519B (zh) * 2020-09-26 2022-08-26 安徽金禾实业股份有限公司 一种3-甲氧基丙烯酸甲酯的制备方法
CN115322105A (zh) * 2021-05-11 2022-11-11 江苏润安制药有限公司 一种合成艾拉莫德关键中间体的方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5479598A (en) * 1992-10-23 1995-12-26 International Business Machines Corporation Compact graphical parallel program user output interface controlled directly by the parallel computer program
DE69409445D1 (de) * 1993-07-27 1998-05-14 Ibm Prozessüberwachung in einem Mehrfachverarbeitungsanbieter
US6289368B1 (en) * 1995-12-27 2001-09-11 First Data Corporation Method and apparatus for indicating the status of one or more computer processes
US5928323A (en) * 1996-05-30 1999-07-27 Sun Microsystems, Inc. Apparatus and method for dynamically generating information with server-side software objects
FR2751448B1 (fr) * 1996-07-17 1999-01-15 Bull Sa Procede de surveillance en temps reel d'un systeme informatique pour son administration et l'aide a sa maintenance en phase d'exploitation
US6112194A (en) * 1997-07-21 2000-08-29 International Business Machines Corporation Method, apparatus and computer program product for data mining having user feedback mechanism for monitoring performance of mining tasks
US6119165A (en) * 1997-11-17 2000-09-12 Trend Micro, Inc. Controlled distribution of application programs in a computer network
US6100887A (en) * 1997-12-05 2000-08-08 At&T Corporation Reusable reversible progress indicator software component for a graphical user interface
CN1324013C (zh) * 1997-12-31 2007-07-04 辉瑞产品公司 芳基稠合氮杂多环化合物
US6605610B1 (en) * 1997-12-31 2003-08-12 Pfizer Inc Aryl fused azapolycyclic compounds
US6151357A (en) * 1998-01-16 2000-11-21 Aspect Communications Corporation Method and apparatus for displaying a visual indication of a transmission status
US6108003A (en) * 1998-03-18 2000-08-22 International Business Machines Corporation Maintaining visibility and status indication of docked applications and application bars
CA2330576A1 (en) * 1998-04-29 1999-11-04 Pfizer Products Inc. Substituted benzazocines as nicotine-binding inhibitors
FR2788982B1 (fr) * 1999-02-02 2002-08-02 Synthelabo Compositions pharmaceutiques contenant de la nicotine et leur application dans le sevrage tabagique
EP1194399A2 (de) * 1999-07-02 2002-04-10 Prescient Neuropharma Inc. Neue aminoitane
IL137937A0 (en) * 1999-08-27 2001-10-31 Pfizer Prod Inc A pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal
US20010036943A1 (en) * 2000-04-07 2001-11-01 Coe Jotham W. Pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines
US20010036949A1 (en) * 2000-05-09 2001-11-01 Coe Jotham Wadsworth Pharmaceutical composition and method of treatment of diseases of cognitive dysfunction in a mammal
US20020010192A1 (en) * 2000-06-02 2002-01-24 Coe Jotham Wadsworth Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss
US20020016334A1 (en) * 2000-07-31 2002-02-07 Coe Jotham Wadsworth Pharmaceutical composition for the treatment of attention deficit hyperactivity disorder (ADHD)

Also Published As

Publication number Publication date
KR100551183B1 (ko) 2006-02-13
PL366657A1 (en) 2005-02-07
CN1503781A (zh) 2004-06-09
AR035957A1 (es) 2004-07-28
JP2004527545A (ja) 2004-09-09
PT1383733E (pt) 2008-04-15
HUP0303811A2 (hu) 2004-03-01
CZ20032814A3 (cs) 2004-08-18
WO2002085843A2 (en) 2002-10-31
ATE388135T1 (de) 2008-03-15
WO2002085843A3 (en) 2003-06-05
IL157881A0 (en) 2004-03-28
KR20030092087A (ko) 2003-12-03
EP1383733A2 (de) 2004-01-28
US20060079707A1 (en) 2006-04-13
RU2003130751A (ru) 2005-03-27
YU78303A (sh) 2006-05-25
ES2300430T3 (es) 2008-06-16
ZA200307205B (en) 2004-09-15
DE60225433T2 (de) 2008-06-12
US7186870B2 (en) 2007-03-06
TWI244472B (en) 2005-12-01
CN1321107C (zh) 2007-06-13
HUP0303811A3 (en) 2008-05-28
AU2002234836B2 (en) 2007-08-23
US7091372B2 (en) 2006-08-15
DK1383733T3 (da) 2008-06-09
BR0208992A (pt) 2004-04-27
RU2282619C9 (ru) 2006-12-20
CA2443946A1 (en) 2002-10-31
US20030060624A1 (en) 2003-03-27
AR043636A2 (es) 2005-08-03
HK1062170A1 (en) 2004-10-21
EP1383733B1 (de) 2008-03-05
RU2282619C2 (ru) 2006-08-27
MXPA03009527A (es) 2004-02-12

Similar Documents

Publication Publication Date Title
DE60225433D1 (de) Verfahren zur herstellung von 1,3-substituierte indene und aryl-annellierte azapolycyclische verbindungen
DE69942641D1 (de) Verfahren zur Herstellung von 1,1,1,3,3-Pentafluorpropan
DE50212243D1 (de) Prozess zur herstellung von aryl-aryl gekoppelten verbindungen
DE50201891D1 (de) Verfahren zur herstellung von 1-octen
DE50213682D1 (de) Verfahren zur herstellung von hydrogen-bis(chelato)boraten und alkalimetall-bis(chelato)boraten
DE60223070D1 (de) Verfahren zur herstellung von dihalogenadamantanen
DE60219193D1 (de) Verfahren zur herstellung von silylorganomercaptanen
DE60208738D1 (de) Verfahren zur Herstellung von Chlorfluorpolyoxyalkylenolen
DE60239842D1 (de) Verfahren zur Herstellung von 10,11-dihydro-10-oxo-5h-dibenzoÄb,fÜazepin-5-carboxamid
DE50210487D1 (de) Verfahren zur Herstellung von 1-Amino-4-hydroxyanthrachinonen
DE60141735D1 (de) Verfahren zur Herstellung von Ethylencopolymeren und die erhaltenen Ethylencopolymere
DE60121522D1 (de) Verfahren zur Herstellung von Ethylencopolymeren und die erhaltenen Ethylenecopolymere
DE60210778D1 (de) Verfahren zur herstellung von 4-amino-2,5-bisheterocyclylchinazolinen
DE10085452T1 (de) Verfahren zur Herstellung von 1,1,1,2-Tetrafluorethan
DE60209171D1 (de) Verfahren zur Herstellung von Bromfluorenen
DE60222806D1 (de) Verfahren zur herstellung von (1,4,5)-oxadiazepinderivaten
DE69936449D1 (de) Verfahren zur herstellung von 1,3-disubstituierten-4-oxocyclischen harnstoffen
DE69913635D1 (de) Verfahren zur Herstellung von 1,3-Dialkyl-2-Imidazolinonderivaten
DE60104789D1 (de) Verfahren zur Herstellung von 2,4,5-Trialkylbenzaldehyden
DE69920003D1 (de) Verfahren zur herstellung von 1,3-disubstituierten-4-oxocyclischen harnstoffen
DE60004931D1 (de) Kontinuierliches Verfahren zur Herstellung von 3,5,5-Trimethylcyclohexa-3-en-1-on(beta-Isophoron)
DE60002254D1 (de) Verfahren zur Herstellung von 4,6-diaminoresorcin
DE60230097D1 (de) Verfahren zur herstellung von 1,5-diaminonaphthalinen
DE60208551D1 (de) Verfahren zur herstellung von racemischen und enantiomerenreinen derivaten von 1,5-diaryl-3-trifluormethyl-delta2-pyrazolinen
DE50000074D1 (de) Verfahren zur Herstellung von halogenierten 1,2-Disilaethanen

Legal Events

Date Code Title Description
8381 Inventor (new situation)

Inventor name: SINGER, ROBERT ALAN, GROTON, CT, US

Inventor name: MCKINLEY, JASON DANIEL, GROTON, CT, US

8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee